Integra LifeSciences Holdings Co. (NASDAQ:IART) Receives $23.00 Consensus Target Price from Brokerages

Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) have earned a consensus recommendation of “Reduce” from the eight ratings firms that are currently covering the company, MarketBeat reports. Three analysts have rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $23.00.

IART has been the topic of several recent research reports. Morgan Stanley started coverage on shares of Integra LifeSciences in a research report on Monday, December 2nd. They set an “underweight” rating and a $20.00 target price on the stock. Truist Financial lowered their price objective on Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating for the company in a research note on Monday, October 14th. Bank of America cut their target price on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating on the stock in a research report on Monday, October 7th. Citigroup raised their price target on Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a research report on Tuesday, November 5th. Finally, BTIG Research raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a research note on Monday, October 7th.

Insider Buying and Selling

In related news, EVP Michael J. Mcbreen sold 1,700 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $24.16, for a total value of $41,072.00. Following the transaction, the executive vice president now owns 56,182 shares of the company’s stock, valued at $1,357,357.12. This represents a 2.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 3.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Integra LifeSciences

Several institutional investors have recently made changes to their positions in the company. KBC Group NV increased its position in Integra LifeSciences by 65.2% during the 3rd quarter. KBC Group NV now owns 2,839 shares of the life sciences company’s stock valued at $52,000 after purchasing an additional 1,120 shares during the period. Exchange Traded Concepts LLC increased its holdings in Integra LifeSciences by 6.5% during the third quarter. Exchange Traded Concepts LLC now owns 33,403 shares of the life sciences company’s stock valued at $607,000 after buying an additional 2,036 shares during the period. New York State Teachers Retirement System raised its stake in Integra LifeSciences by 3.0% in the third quarter. New York State Teachers Retirement System now owns 90,098 shares of the life sciences company’s stock worth $1,637,000 after buying an additional 2,616 shares in the last quarter. Nisa Investment Advisors LLC lifted its holdings in Integra LifeSciences by 599.6% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company’s stock worth $74,000 after buying an additional 2,800 shares during the period. Finally, Canada Pension Plan Investment Board bought a new stake in Integra LifeSciences during the 2nd quarter valued at $114,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Price Performance

Shares of Integra LifeSciences stock opened at $26.34 on Friday. The firm has a market cap of $2.03 billion, a PE ratio of -292.63, a PEG ratio of 0.83 and a beta of 1.16. The stock has a 50 day moving average of $23.59 and a 200 day moving average of $22.28. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. Integra LifeSciences has a 12 month low of $16.81 and a 12 month high of $45.42.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Monday, November 4th. The life sciences company reported $0.41 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.02. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm had revenue of $380.80 million during the quarter, compared to the consensus estimate of $375.81 million. During the same period in the prior year, the company earned $0.76 EPS. The company’s quarterly revenue was down .4% compared to the same quarter last year. On average, research analysts expect that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.